Metraipolis › archive › dc_7df493a5b17c

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer — Europe PMC PMID:41225509

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41225509
DOI
10.1186/s12967-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-08T15:46:22.105Z
SHA-256 of the archived text
2598f8c279c47ed21cfaecb91ddd005bf24336d409a99f344bfa18984aaa34fb
Stable URL of this page
https://metraipolis.com/documento/dc_7df493a5b17c

How to cite

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer — Europe PMC PMID:41225509 — Europe PMC (en), https://europepmc.org/article/MED/41225509 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7df493a5b17c (Metraipolis archive dc_7df493a5b17c, sha256 2598f8c279c47ed21cfaecb91ddd005bf24336d409a99f344bfa18984aaa34fb)
BibTeX
@misc{dc7df493a5b17c,
  title = {Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer — Europe PMC PMID:41225509},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41225509},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7df493a5b17c; sha256 2598f8c279c47ed21cfaecb91ddd005bf24336d409a99f344bfa18984aaa34fb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41225509. Agents can read the archived copy with the MCP tool read_document.